Live feed16:05:00·12dPRReleasevia QuantisnowShattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8ByQuantisnow·Wall Street's wire, on your screen.STTK· Shattuck Labs Inc.Health Care
